Tag Archives: Vanda

Solicitor General’s Vanda Brief Deconstructs Mayo

Posted on March 19, 2020 by Warren Woessner

When I was writing my post on INO Therapeutic’s Petition for Cert. on March 16th, I noticed the cite to the “invitation brief in Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals Inc., No. 18-817 (U.S. Dec. 6, 2019)(“the brief”). While … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

INO v. Praxair – Time for the Supreme Court to Step Up to the Plate?

Posted on March 16, 2020 by Warren Woessner

Before you read this post, please back up and read my post of September 3, 2019 which discusses the Fed. Cir.’s ruling that the claims of U.S. Pat. No. 8,794,742 are patent-ineligible as attempts to claim a natural phenomenon. The … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

Supreme Court Denies Cert. in Vanda, Berkheimer and Athena

Posted on January 13, 2020 by Warren Woessner

This morning, the Supreme Court denied the petitions for cert. filed in the Vanda, Berkheimer and Athena appeals. While the Court had requested and received amici briefs from the Solicitor General that opined that the Court should not grant cert. … Continue reading →

Posted in Supreme Court News | Tagged , , | Leave a comment

PTO Issues Section 101 Memorandum after Vanda Decision

Posted on June 11, 2018 by Warren Woessner

I have posted twice recently on the Fed. Cir.’s opinion in Vanda Pharms., Inc. v. West-Ward Pharm. Int’l, Ltd., Appeal no. 2016-2107 (Fed. Cir., April 18, 2018). The Fed. Cir. affirmed the district court’s ruling that Vanda’s claims in U.S. … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment